论文部分内容阅读
目前尚不清楚超出推荐值的强化降压是否更能降低高血压患者的左心室肥厚(left ventricular hypertrophy,LVH)发生风险,以及LVH风险降低能否解释强化降压的益处。Soliman等纳入收缩压干预试验(systolic blood pressure intervention,SPRINT)中患有高血压但无糖尿病的8164例受试者(平均年龄67.9岁,女性35.3%,31.2%为非洲裔),分为强化降
It is unclear whether intensified antihypertensive beyond recommended levels can lower the risk of left ventricular hypertrophy (LVH) in hypertensive patients and whether the reduced risk of LVH can explain the benefits of intensive antihypertensive therapy. Soliman et al. Included 8164 subjects with hypertension but no diabetes (mean age 67.9 years, 35.3% women and 31.2% African American) in systolic blood pressure intervention (SPRINT)